(Q34662893)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Richard F. Kefford

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Georgina V. Long

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

2

Lauren E Haydu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

4

Mary W F Azer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

6

Megan Lyle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

8

Alexander Guminski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Matthew M K Chan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Oliver Klein

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Arthur Clements

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

English

0 references

publication date

1 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

3142-3153

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

NRAS mutation status is an independent prognostic factor in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Drug rechallenge and treatment beyond progression--implications for drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28851

21 January 2018

Identifiers

DOI

10.1002/CNCR.28851

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24985732%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference